In a phase I/II trial of HER2-positive advanced gastric cancer, poziotinib in combination with paclitaxel and trastuzumab demonstrated a PFS of 13 weeks and an OS of 29.5 weeks [88]. This evidence concerns the gene ERBB2 and gastric cancer.